Kriya Biosciences offers innovative drug delivery solutions built around its proprietary bioavailability enhancement technology platform – APERI. Our core business strategy is to license and partner our proprietary technology platform to commercialize innovative pharmaceuticals. Our partners leverage our expertise to employ our unique paracellular drug transport mechanism to advance their early stage portfolio as well as to extend lifecycle for their existing products.